MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

mindmed reports second quarter 2022 financial results and business highlights

Pressbee - PR Newswire :

Watch the post from MindMed Reports Second Quarter 2022 Financial Results and Business Highlights, Now to the details :

– Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 – – Advanced IND-enabling studies for MM-402 with the Phase 1 investigator-initiated pharmacokinetic/pharmacodynamic trial on track to initiate in Q3 2022 –...

For more, read the news from the source

MindMed Reports Second Quarter 2022 Financial Results and Business Hig

This was the summery for MindMed Reports Second Quarter 2022 Financial Results and Business Highlights We hope that we have succeeded by sharing the full details of this topic.

PR Newswire MindMed Reports Second Quarter 2022 Financial Results and Business Highlights – Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 – – Advanced IND-enabling studies for MM-402 with the Phase 1 investigator-initiated pharmacokinetic/pharmacodynamic trial on track to initiate in Q3 2022 –...

Please note that the original topic has been published and is available on PR Newswire the editing team at PressBee have verified it and it may have been partially modified or quoted from it. You can read and follow this news or topic from its main source.

( PRESSBEE ) An independent news reader does not assume any liability for the material published in it because it does not express the opinion of the site.